Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04567849 · ClinicalTrials.gov registry record · NA
Decreasing ED Utilization by Nudging Patients to Call Their Providers
A NA study, sponsored by Geisinger Clinic.
- Completed
- Registry status
- NA
- Development phase
- 11,546
- Enrollment target
NCT04567849: Completed NA study, sponsored by Geisinger Clinic.
NCT04567849 is a NA study that has completed, run by Geisinger Clinic. The registered enrollment target is 11,546 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (723% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04567849, a NA study, has completed, sponsored by Geisinger Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 11,546 participants
- Enrollment target
Study Summary
In the present study, patients will be sent a message shortly after completing a medical procedure that informs or reminds them that they can reach out to Geisinger, and how to do it, if they have any medical issues or concerns. Researchers will assess if such messages make patients more likely to contact Geisinger with post-procedure medical concerns and decrease emergency department utilization.
Primary Outcome
Proportion of patients who call the tele-nurse or their provider within 30 days of their appointment
Interventions
- BEHAVIORAL message
- BEHAVIORAL provider
- BEHAVIORAL tele-nurse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,546 participants |
| Start Date | 2021-11-16 |
| Est. Completion | 2023-06-15 |
| Phase | NA |
What the finished NCT04567849 record still lists
NCT04567849 is an interventional study that assigns participants to a tested intervention. Its 11,546 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (723% higher).
The record links to 0 conditions, and to 3 interventions - of which message is the first listed.
NCT04567849 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04567849 about?
NCT04567849 is a clinical study titled "Decreasing ED Utilization by Nudging Patients to Call Their Providers". In the present study, patients will be sent a message shortly after completing a medical procedure that informs or reminds them that they can reach out to Geisinger, and how to do it, if they have any medical issues or concerns. Researchers will assess if such messages make patients more likely to c...
What is the current status of trial NCT04567849?
This trial is currently completed. It is a NA study. The enrollment target is 11,546 participants. The study started on 2021-11-16. Estimated completion is 2023-06-15.
What interventions are being tested in trial NCT04567849?
The interventions under investigation include: message (BEHAVIORAL), provider (BEHAVIORAL), tele-nurse (BEHAVIORAL).
Who is sponsoring clinical trial NCT04567849?
This trial is sponsored by Geisinger Clinic, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04567849's enrollment target sits among peer trials
11,546 14th of 2000 higher than 1,987 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06677060 · 11,300 participants · Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
- NCT07064473 · 11,800 participants · Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- NCT01772771 · 12,000 participants
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- NCT04937868 · 12,000 participants
Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI